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Androgen receptor AR 
Androgen response element ARE 
ATP-binding cassette ABC 
Chromatin immunoprecipitation ChIP 
Cytochrome P450 CYP 
D-dopachrome tautomerase DDT 
Dihydrotestosterone DHT 
Farnesoid X receptor FXR 
HMG-CoA reductase HMGCR 
HMG-CoA synthase 1 HMGCS1 
25-Hydroxycholesterol 25HC 
6β-Hydroxytestosterone 6βHT 
7α-Hydroxy-4-cholesten-3-one C4 
Knockout KO 
Low-density lipoprotein receptor LDLR 
Liver X receptor α LXRα 
Multidrug resistance 1a Mdr1a 
Niemann-Pick C1-like 1 NPC1L1 
Organic anion transporting polypeptide 2 OATP2 
Phosphate buffered saline PBS 
Pregnane X receptor PXR 
Proliferator-activated receptor γ coactivator-1α PGC1α 
Protein kinase C delta PRKCD 
Sex hormone–binding globulin SHBG 
Small heterodimer partner SHP 
Spermine-binding protein SBP 
Squalene epoxidase SQLE 
SREBP cleavage-activating protein SCAP 
Steroid 5α-reductase 2 SRD5A2 
Sterol regulatory element binding protein 2 SREBP2 
Sterol regulatory element-binding factor 2 SREBF2 
Sterol response element SRE 
Sulfotransferase 2a1 SULT2A1 
TATA-binding protein TBP 
Wild type WT 
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Introduction 
CYP3A subfamily consists of four and six isoforms in human and mouse, respectively. 
CYP3A isoforms are abundantly expressed in the liver and small intestine which are critical tissues 
for drug metabolism. More than 50% of clinically used drugs are metabolized by CYP3A. Thus, 
CYP3A is the most important cytochrome P450 isoforms responsible for drug metabolism [1]. In 
addition, CYP3A catalyzes hydroxylation of endogenous compounds such as bile acids, steroid 
hormones and vitamins [2-5]. For example, cholesterol and testosterone are metabolized by CYP3A 
to their inactive forms, 25-hydroxycholesterol (25HC) and 6β-hydroxytestosterone (6βHT), 
respectively, in both human and mouse [6-7]. Thus, CYP3A may play some role in the regulation of 
physiological levels of endogenous compounds in the body. 
Cholesterol is one of components of cellular membrane, which is supplied from endogenous 
synthesis and diet. A master regulator of cholesterol homeostasis is sterol regulatory element binding 
protein 2 (SREBP2) which regulates synthesis and uptake of cholesterol [8]. When cellular cholesterol 
levels are decreased, SREBP cleavage-activating protein (SCAP) escorts SREBP2 from endoplasmic 
reticulum membrane to Golgi body where SREBP2 is processed to an active form [8]. The activated 
SREBP2 translocates to nucleus, and activates transcription of genes involved in synthesis and uptake 
of cholesterol [8]. On the other hand, under the high cholesterol condition, formation rate of 25HC is 
increased, and increased 25HC effectively suppresses activation of SREBP2 by disturbing 
disengagement of SREBP2 from endoplasmic reticulum membrane, which leads suppression of 
cholesterol synthesis and uptake [9]. Thus, the formation of 25HC by CYP3A is considered to be a 
feedback mechanism which is responsible for the maintenance of cholesterol homeostasis. However, 
not only CYP3A but also cholesterol 25-hydroxylase, CYP27A1 and auto-oxidation are involved in 
the formation of 25HC [10-13]. Therefore, the physiological role of CYP3A as an enzyme catalyzing 
cholesterol 25-hydroxylation to maintain cholesterol homeostasis remains obscure, and the possibility 
that 25-hydroxylation of cholesterol by CYP3A is involved in the regulation of synthesis and uptake 
of cholesterol in liver should be examined. 
Testosterone is a major androgen in human plasma. Testosterone provided from systemic 
circulation contributes to development and functions of prostate through activation of androgen 
receptor (AR) [14]. In addition, androgen enhances cholesterol synthesis in prostate by the following 
mechanism. Prostatic AR activated by androgen increases expression levels of SCAP, which 
sequentially enhances cholesterol synthesis through SREBP2 activation [15, 16]. On the other hand, 
circulating testosterone is mainly converted to inactive form in liver [17]. Since CYP3A metabolizes 
testosterone into 6βHT which has negligible potency to activate AR, hepatic CYP3A is considered to 
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contribute to the inactivation of testosterone in the body [17, 18]. However, to what extent CYP3A 
contributes to the overall inactivation of testosterone in the body remains to be clarified. In addition, 
whether alteration of CYP3A activity affects cholesterol synthesis via AR-SCAP-SREBP pathway in 
prostate also remains to be clarified. 
The generation of gene knockout mice has provided a useful tool in understanding the gene 
function. Previously, van Herwaarden et al have shown the effect of Cyp3a deficiency on 
detoxification of docetaxel using Cyp3a knockout mice [19]. However, the effect of Cyp3a deficiency 
on physiological functions of Cyp3a has not been elucidated. Therefore, the purpose of this study is to 
clarify the potential role of Cyp3a in cholesterol synthesis in liver and prostate. In the chapter 1, the 
effect of Cyp3a deficiency on cholesterol synthesis, and its effect on bile acid synthesis which is 
initiated from cholesterol hydroxylation, were investigated using Cyp3a-/- mice. In the chapter 2, the 
effect of Cyp3a deficiency on testosterone levels in plasma, and cholesterol synthesis in prostates were 
investigated using Cyp3a-/- mice.   
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ChapterⅠ 
Studies on the effects of Cyp3a deficiency on  
cholesterol and bile acid synthesis in liver 
6 
 
1-1. Introduction 
Cholesterol has multifunctional roles as components of cellular membranes and precursors of 
biological molecules such as steroid hormones, oxysterols, vitamins and bile acids in humans and 
animals [20-23]. The endogenous synthesis of cholesterol is catalyzed by many enzymes including 
HMG-CoA synthase 1 (HMGCS1), HMG-CoA reductase (HMGCR) and squalene epoxidase (SQLE). 
When cellular sterol levels are low, SREBP2 is processed by proteases and translocates into the nucleus. 
Nuclear SREBP2 activates the transcription of genes encoding enzymes involved in the biosynthesis 
of cholesterol [24]. Thus, SREBP2 is considered as a master regulator of cholesterol biosynthesis [8].  
Hepatic cholesterol levels are regulated by elaborate networks such as influx, efflux, and 
conversion into bile acids in addition to biosynthesis. Dietary cholesterol is absorbed from the jejunum 
and transported to the liver [25]. A part of cholesterol in the liver is enclosed in lipoprotein and excreted 
into blood circulation. Hepatic cholesterol is also secreted into the duodenum via the biliary canaliculus. 
Most of the biliary cholesterol is reabsorbed in the jejunum with dietary cholesterol and transported 
back to the liver [25]. Such behavior of cholesterol is regulated by many transporters. For example, 
Niemann-Pick C1-like 1 (NPC1L1) imports cholesterol from the lumen into enterocytes of the intestine 
[26]. At the basolateral membrane of the intestine, ATP-binding cassette (ABC) A1 transports 
cholesterol into the bloodstream. In the liver, ABCA1 also functions at basolateral surface to transport 
cholesterol into the bloodstream [27]. ABCG5 and ABCG8 form a functional heterodimer complex 
that mediates the secretion of cholesterol from hepatocytes into the biliary canaliculus and also the 
apical efflux of cholesterol from enterocytes into the lumen of the intestine [28, 29]. Hepatic low-
density lipoprotein receptor (LDLR) is responsible for uptake of LDL cholesterol from blood 
circulation into hepatocytes [30]. On the other hand, a part of cholesterol in the liver is metabolized to 
bile acids through many steps catalyzed by enzymes such as CYP7A1 and CYP8B1 [31]. Bile acids 
are excreted into the biliary canaliculus with cholesterol and then assist the absorption of biliary and 
dietary cholesterol in the intestine. 
Members of the CYP3A subfamily are the most abundant CYP enzymes in the liver and small 
intestine. CYP3A enzymes metabolize over 50% of drugs in clinical use and are therefore closely 
involved in pharmacokinetics, drug interactions, drug efficacy and toxicity [1]. CYP3A enzymes 
metabolize not only xenobiotics but also many endogenous compounds such as cholesterol, bile acids, 
steroid hormones and vitamins. The extremely wide substrate specificity of CYP3A enzymes has 
resulted in versatile physiological functions of CYP3A [2-5]. As for cholesterol, it has been reported 
that human CYP3A4 mediates the conversion of cholesterol into 4β-HC, an endogenous oxysterol [32, 
33]. 4β-HC is expected to be useful as an endogenous marker of CYP3A because it is found in human 
circulation [5]. In addition, a recent study demonstrated that CYP3A was involved in 25-hydroxylation 
of cholesterol [6]. 25-HC acts as not only a precursor of bile acids but also a physiologically active 
oxysterol that suppresses SREBP2 and down-regulates cholesterol biosynthesis [9, 34, 35]. However, 
the roles of cholesterol metabolites formed by CYP3A in biosynthesis of cholesterol have not been 
fully elucidated, particularly in in vivo experiments.  
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The Cyp3a-knockout (Cyp3a-/-) mouse is a valuable research tool in studies on drug 
metabolism and drug-induced toxicity in vivo [19, 36]. However, the physiological role of CYP3A 
has not been clearly elucidated in in vivo experiments. To reveal the role of CYP3A in cholesterol 
homeostasis, we investigated the effects of CYP3A deficiency on expression levels of genes 
responsible for influx, efflux, metabolism and biosynthesis of cholesterol using Cyp3a-/- mice.  
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1-2. Materials and Methods 
 
1-2-1. Chemicals 
 
7α-Hydroxy-4-cholesten-3-one (C4) was purchased from Santa Cruz (Santa Cruz, CA). 25HC 
was purchased from Steraloids (Newport, RI). Lathosterol was purchased from Sigma-Aldrich (St. 
Louis, MO). Acetonitrile, chloroform, hexane and methanol were HPLC grade (Wako, Tokyo, Japan). 
 
1-2-2. Animals 
 
C57BL/6JJcl mice (CLEA, Tokyo, Japan) were used as wild type (WT) mice. Recently, we 
generated Cyp3a-/- mice by targeted deletion of endogenous Cyp3a genes [37]. Brief, Cyp3a13-/- lines 
and Cyp3a57-59-/- lines were generated by conventional gene targeting and Cre-loxP mediated 
chromosomal deletion, respectively, and the two lines were mated to generate Cyp3a-/- mice lacking 
the mouse Cyp3a gene cluster. The distance between the Cyp3a57-59 gene cluster and a Cyp3a13-/- 
gene is ~5 Mb and several genes are located between the loci, so the two knockout lines were generated 
independently. It has been confirmed that the six genes on the mouse Cyp3a cluster 
(Cyp3a13/57/44/11/25/59) were expressed in the livers and intestines of WT mice but not in those of 
Cyp3a-/- mice [37]. Fetal specific Cyp3a16 and female specific Cyp3a41 were not detected at mRNA 
levels because only adult male mice were used in this study (data not shown). In addition, α- and 4-
hydroxylation activities of triazolam, which are catalyzed by mouse CYP3A [38], in the liver 
microsomes of Cyp3a-/- mice were less than 7% of those in WT mice (Fig. 1). These findings suggest 
the complete deletion of CYP3A functions in Cyp3a-/- mice used in the present study. The control 
genetic background is almost same as Cyp3a-/- mice, because Cyp3a-/- mice were backcrossed to 
C57BL/6JJcl mice at least 4 times. All experiments were done using male mice between 10 and 11 
weeks of age. Animals were kept in a temperature-controlled environment with a 12-hr light/dark cycle. 
The light-cycle hours were between 7 AM and 7 PM. They received a standard diet containing 0.1% 
cholesterol (CE-2, CLEA, Tokyo, Japan, Table 1). Animals were sacrificed between 10 AM and 11 
AM without fast. The present study was conducted in accordance with the guidelines for the Care and 
Use of Laboratory Animals, as adopted by the Committee on Animal Research of Tottori University 
and Chiba University. 
 
1-2-3. RNA isolation and cDNA synthesis 
 
Total RNA was isolated from tissue pieces of livers and small intestines. Since most of 
cholesterol is reabsorbed in jejunum [25], the upper parts of small intestines (1-cm segments collected 
at 10 cm from the pyloric region) were used. Total RNA was extracted by using ISOGEN (Nippon 
Gene, Tokyo, Japan) and was purified using RNeasy columns (Qiagen, Hilden, Germany) were used 
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in accordance with the manufacturer’s instructions, and then treated with RNase-free DNase I (Wako 
Pure Chemicals, Osaka, Japan). The cDNA was generated with a random hexamer by using a High-
Capacity cDNA Reverse Transcription Kit (Applied Biosytems, Foster, CA). 
 
1-2-4. Analysis of mRNA levels 
 
Expression levels were measured by quantitative real-time PCR carried out on an EcoReal-
time PCR system (Illumina, Hayward, CA). Expression levels of HMGCS1, HMGCR, SQLE, sterol 
regulatory element-binding factor 2 (SREBF2), ABCG5, ABCG8, ABCA1, LDLR, NPC1L1, 
CYP7A1, CYP8B1, CYP27A1, CYP7B1 and small heterodimer partner (SHP), organic anion 
transporting polypeptide (OATP2) and sulfotransferase 2a1 (SULT2A1) were measured by SYBR 
Green based real-time PCR using KAPA SYBR Fast ABI Prism 1000 (KAPA Biosystems, Woburn, 
MA). Specific primers for real-time PCR are presented in Table 2. Expression levels of CYP2C55, 
CYP2B10 and multidrug resistance 1a (Mdr1a) mRNA were measured using TaqMan Gene 
Expression Assays. (Mm00472168_m1, Mm00456591_m1 and Mm00440761_m1, Applied 
Biosystems). The expression levels of mRNA were normalized with the expression level of mouse 
GAPDH as an endogenous control gene. 
 
1-2-5. Preparation of nuclear extracts 
 
Nuclear fractions were prepared from liver tissues. Aliquots of frozen liver (about 100 mg) 
were homogenized in 1 ml of lysis buffer (10 mM HEPES adjusted to pH 7.9, 1.5 mM MgCl2 and 10 
mM KCl) supplemented with protease inhibitor cocktail set III (Calbiochem, La Jolla, CA) and 1 mM 
DTT. The liver homogenate was centrifuged at 10,000 × g for 5 min at 4°C. The supernatant (cytosol 
fraction) was removed and stored at -80°C. The nuclear pellet was resuspended in 0.15 ml extraction 
buffer (20 mM HEPES adjusted to pH 7.9, 2.5% glycerol, 0.42 M NaCl and 1.5 mM MgCl2) 
supplemented 1 mM DTT and protease inhibitor cocktail set III. The suspension was rotated at 4°C 
for 30 min and centrifuged at 20,000 × g for 15 min at 4°C. The supernatant from this spin was 
designated as the nuclear extract and stored at -80°C until use. 
 
1-2-6. Western blot analysis 
 
Nuclear extracts (30 μg/lane) were separated by 10% SDS-polyacrylamide gel electrophoresis 
and transferred to a nitrocellulose membrane. After 1-hr incubation with blocking buffer (0.05% 
Tween 20 in PBS containing 3% skim milk), the membrane was probed for 1 hr at room temperature 
using a polyclonal anti-SREBP2 rabbit antibody (1:500 dilution, Ab2848, Abcam, Cambridge, UK). 
A monoclonal anti-TATA-binding protein (TBP) mouse antibody (1:2000 dilution, Ab818, Abcam) 
was used as an internal control. After washing, the membrane was incubated with a peroxidase-
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conjugated secondary antibody for 1 hr at room temperature. The secondary antibodies used were anti-
rabbit IgG (1:100,000 dilution, Sigma-Aldrich) and anti-mouse IgG (1:5000 dilution, Sigma-Aldrich) 
for anti-SREBP2 and anti-TBP antibodies, respectively. The primary and secondary antibodies were 
diluted with 0.05% Tween 20 in PBS containing 3% BSA. Protein bands were visualized by using an 
ECL Western Blotting Detection Reagents (GE Healthcare, Buckingham, UK), ImmunoStar LD 
(Wako) and LAS-1000 plus (Fujifilm, Tokyo, Japan). 
 
1-2-7. Chromatin immunoprecipitation (ChIP) assay 
 
Liver tissue (100 mg) of WT and Cyp3a-/- mice was minced and formaldehyde was added to 
a final concentration of 1%. After rocking at room temperature for 15 min, glycine was added to a final 
concentration of 0.125 M to stop the cross-linking. The tissues were collected by centrifugation and 
were homogenized by a dounce homogenizer in cold cell lysis buffer (5 mM PIPES, pH 8.0, 85 mM 
KCl, 0.5% Nonidet P-40) supplemented with proteinase inhibitor cocktail set III (Calbiochem). Nuclei 
pellets were collected by centrifugation at 6,200 × g for 10 min at 4°C and resuspended in 400 μl of 
nuclei lysis buffer (50 mM Tris-HCl, pH 8.1, 10 mM EDTA, 1% SDS) supplemented with proteinase 
inhibitor cocktail set III (Calbiochem). Nuclei were sonicated before immunoprecipitation with 
polyclonal anti-SREBP2 rabbit antibody (ab28482, Abcam) or normal IgG (sc2027, Santa Cruz, CA) 
overnight at 4°C. DNA in the precipitated samples was reverse cross-linked at 65°C for 6 hr, and the 
DNA was recovered by phenol/chloroform extraction and ethanol precipitation. DNA samples were 
measured by semi-quantitative PCR with Go Taq® Green Mater Mix (Promega, Madison, WI) and 
quantitative PCR using SYBR Green based real-time PCR with KAPA SYBR Fast ABI Prism 1000 
(KAPA Biosystems). PCR was carried out with Hmgcs1-specific primers encompassing the sterol 
regulatory elements (SRE) site in the 5’-flanking region (-348 to -208 bp) and a region in intron 5 
(+11862 to +11948 bp) as a negative control. The PCR conditions were one cycle of pre-denaturation 
at 95°C for 10 min, 45 cycles of denaturation at 95°C for 15 sec, annealing at 58°C for 30 sec, and 
elongation at 72°C for 15 sec. The primers used are as follows: Hmgcs1/SRE, 5’-
ATTGGTCGGAGAACCTCTC-3’ and 5’-AGGGGTGGGAACAAAGTCC-3’: Hmgcs1/negative 
control, 5’-ATTAGACAGGATTTGGGGTCACT-3’ and 5’-GTCTACACTGCAAAGAGAGCAGG-
3’. 
 
1-2-8. Cholesterol analysis 
 
Hepatic lipids were extracted according to the procedure of Bligh and Dyer [39] with slight 
modification. Briefly, frozen liver tissues (about 5 mg) were homogenized and extracted with a mixture 
of chloroform/isopropanol/Triton X-100 (7:11:0.1, v/v/v). The organic layer was subjected to 
cholesterol determination after evaporation and resuspension in methanol. Total cholesterols in liver 
and plasma were determined by use of a Cholesterol E-Test Wako kit (Wako) according to the 
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manufacturer’s instructions. 
 
1-2-9. Analysis of plasma lathosterol 
 
Concentration of lathosterol in plasma was determined by an HPLC method. To extract lipids, 
plasma (0.1 ml) was diluted with 0.1 ml of distilled water and vigorously mixed with 0.8 ml of hexane 
for 1 min, and then centrifuged at 2000 × g for 5 min. The supernatant (hexane layer) was transferred 
to a new tube and further extracted once with 0.2 ml of water. Separately the water layer was further 
extracted twice with 0.8 ml of hexane. The hexane extracts were combined, and dried under vacuum. 
The residue was reconstituted with 0.1 ml of methanol, and 50 μl of 15 reconstituted sample was 
injected onto a Hitachi L-7000 model of HPLC system (Tokyo, Japan) and Poroshell120 EC-C18 (3.0 
× 100 mm, 2.7 μm) column (Agilent technology, Santa Clara, CA). The mobile phase consisted of 
acetonitrile/methanol (8:2, v/v) at a flow rate of 0.6 ml/min. The eluent was monitored at a wavelength 
of 235 nm. 
 
1-2-10. Analysis of 25HC in the liver 
 
Concentration of 25HC in the liver was determined by methods described elsewhere [6] with 
slight modifications. In brief, liver tissues (50 mg) were homogenized in 0.1 M potassium phosphate 
buffer (pH 7.4) containing 4 mM MgCl2, 1 mM EDTA and 30 mM nicotinamide. The homogenates 
were incubated with 1 N ethanolic potassium hydroxide, extracted with hexane and derivatized to 
picolinyl esters. The samples were analyzed by HPLC-MS/MS using Triple TDFTM 5600 System (AB 
SCIEX, Framingham, MA). 
 
1-2-11. Analyses of total bile acids and their intermediary product C4 
 
Bile acid levels in the liver were determined following bile acid extraction of liver tissues. 
Briefly, liver tissues (200 mg) were homogenized in 1 ml of ethanol and heated at 85°C for 1 min and 
then centrifuged at 1000 × g for 5 min. After the supernatant was isolated, the precipitate was extracted 
twice with 1 ml of ethanol and the combined extracts were dried under vacuum. The residue was 
resuspended in 0.2 ml of 75% methanol and centrifuged at 14,000 × g for 10 min, filtered using a filter 
unit (0.45 μm, Millipore, Billerica, MA) and dried under vacuum. The residue was reconstituted with 
10 μl of 75% methanol. After dilution with distilled water, the sample was analyzed by use of total 
bile-Test Wako kit (Wako) according to the manufacturer’s instructions. Size of bile acid pool was 
expressed as sum of total bile acid content in the liver, small intestine and gallbladder per 100 g body 
weight. Bile acid content in small intestine was determined after extraction of small intestine tissues 
(200 mg) as described for bile acid content in the liver. For gallbladder, bile drawn from gallbladder 
was diluted with distilled water of 2 ml/mg tissue of empty gallbladder and analyzed as described 
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above. Concentration of C4, an intermediary product in the synthesis of bile acids, in plasma was 
determined by an HPLC method of Lenicek et al. [40] with slight modifications. Plasma (0.2 ml) was 
vigorously mixed with 2.5 ml of chloroform/methanol (2:1, v/v), and centrifuged at 2000 × g for 3 min. 
After the upper phase was discarded, the lower phase was mixed with 1 ml of 125 mM NaCl in 50% 
methanol, and centrifuged as above. The lower phase was dried under vacuum. The residue was 
reconstituted with 0.2 ml of acetonitrile. Eighty μl of reconstituted sample was injected onto a Hitachi 
L-7000 model of HPLC system and a CAPCELL PAK C18 UG120 column (4.6 mm × 250 mm, 5 μm; 
Shiseido, Tokyo, Japan). The mobile phase consisted of acetonitrile/water (92:8, v/v) at a flow rate of 
1.0 ml/min. The eluent was monitored at a wavelength of 241 nm. 
 
1-2-12. Statistical analysis 
 
Number of mice in each group was described in legends of figures and tables. Data are 
shown as means ± S. E. M. or S. D. Statistical analyses were performed by using Statcel (OMS, 
Saitama, Japan). Comparison was made with Student’s t-test or Welche’s t-test. P < 0.05 was 
considered statistically significant.  
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Table 1.  Nutrient composition of CE-2 diet 
   
Nutrient Composition 
Moisture (%) 8.9 
Crude protein (%) 24.9 
Crude fat (%) 4.6 
Crude fiber (%) 4.1 
Crude ash (%) 6.6 
Nitrogen-free extract (%) 51.0 
Energy (kcal/g)a 3.4 
Note. Values and nutrients are provided in the catalog of CLEA Japan Inc.(2013). 
aPhysiological fuel value with no caloric value for crude fiber. 
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Table 2.  Sequences of primers used in real-time PCR 
Gene Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) 
Hmgcs1 TGGCACAGTACTCACCTC CCTTCATCCAAACTGTGG 
Hmgcr CTTGTGGAATGCCTTGTGATTG AGCCGAAGCAGCACATGAT 
Sqle AAATCAGAGCCGTGGGCTAC GGAAGTGACACAGTTCTATG 
Srebf2 GGTCCTCCATCAACGACAA CTCAGAACGCCAGACTTGTGC 
Abcg5 ATCGCAGCCCAACTCCTTCAG CAGTCCAGTCCTGTGGTTGGC 
Abcg8 GCCACCCTTGTCCTCGCTA TTCTTTGCTGCGTCTGTCGAT 
Abca1 GATGTGGAATCGTCCCTCAGTTC ACTGCTCTGAGAAACACTGTCCTCC 
Ldlr GTGCATGGCTTCATGTAC TCATAGATGGCCAAGGAG 
Npc1l1 TCTACTGTGCCAATGCCCCTCTC CCCGTAGTCAGCTATGCAGCTCA 
Cyp7a1 AGCAACTAAACAACCTGCCAGTACTA GTCCGGATATTCAAGGATGCA 
Cyp8b1 GAAGATCCACCACTACAGCAT GGACAAAGGTCTTCATCTCG 
Cyp27a1 CCAGGCACAGGAGAGTACG GGGCAAGTGCAGCACATAG 
Cyp7b1 GAAAACTCTTCAAAGGCAACATGG ACTGGAAAGGGTTCAGAACAAATG 
Shp TTCAACCCAGATGTGCCAGG CAAATGCTCCTGTTGCAGGTGTGCGA 
Oatp2 ATTCGTGAGTTACTTCGGAACA CCCATAACTGCACATCCTACAC 
Sult2a1 CCTCCCATCTTCCCATCCAT CTCACGAGATAGATCGCCTTGG 
Gapdh TGCACCACCAACTGCTTA GGATGCAGGGATGATGTTC 
15 
 
  
0
0.5
1
1.5
2
WT KO
α
-H
y
d
ro
x
y
la
ti
o
n
 a
c
ti
v
it
y
(n
m
o
l/
m
in
/m
g
 p
ro
te
in
)
**
0
0.5
1
1.5
2
WT KO
4
-H
y
d
ro
x
y
la
ti
o
n
 a
c
ti
v
it
y
 
(n
m
o
l/
m
in
/m
g
 p
ro
te
in
)
**   
BA
Fig. 1.  α-Hydroxylation (A) and 4-hydroxylation (B) activities of triazolam in liver 
microsomes of WT and Cyp3a-/- (KO) mice. 
Triazolam (200 μM) was incubated with liver microsomes of WT and KO mice as described in 
elsewhere (27). Data are shown as means ± S. E. M. of three mice in each group. Liver microsomes 
prepared from each mouse were used for three independent determinations, each performed in 
duplicate. **P < 0.01 versus WT mice.  
 
16 
 
1-3. Results  
 
1-3-1. Effects of CYP3A deficiency on expression levels of enzymes involved in cholesterol 
biosynthesis 
 
We measured the mRNA levels of HMGCS1, HMGCR and SQLE in the livers of WT and 
Cyp3a-/- mice in order to investigate the effects of CYP3A deficiency on mRNA expression of enzymes 
involved in cholesterol biosynthesis. As shown in Fig. 2, expression levels of HMGCS1 and SQLE 
mRNAs in the livers of Cyp3a-/- mice were significantly higher than those of WT mice (5.4 and 4.9 
fold, respectively). Expression levels of HMGCR mRNAs in the livers of Cyp3a-/- mice showed a trend 
toward higher levels than those of WT mice, although the differences were not significant. Expression 
levels of HMGCS1 and SQLE mRNAs in the small intestine were similar between WT and Cyp3a-/- 
mice. Expression levels of HMGCR mRNAs in the small intestines of Cyp3a-/- mice were 1.4-fold 
higher than those of WT mice (Fig. 3). 
 
1-3-2. Effects of CYP3A deficiency on expression of SREBP2 
 
The Srebf2 gene encoding SREBP2 is also known as a target gene of SREBP2 [8]. As shown 
in Fig. 4A, expression levels of SREBF2 mRNA in the livers of Cyp3a-/- mice were 1.9-fold higher 
than those of WT mice (P < 0.001). In the small intestine, expression levels of SREBF2 mRNAs were 
similar between WT and Cyp3a-/- mice (Fig. 3). Since mRNA expression levels of HMGCS1, SQLE 
and SREBF2 in the livers of Cyp3a-/- mice were significantly higher than those of WT mice, we 
determined nuclear levels of SREBP2 protein in the livers of WT and Cyp3a-/- mice. As shown in Fig. 
4B, nuclear levels of SREBP2 protein in the livers of Cyp3a-/- mice were markedly higher than those 
in WT mice. 
 
1-3-3. Effects of CYP3A deficiency on SREBP2 binding to the SRE motif 
 
To verify whether CYP3A deficiency affected binding of SREBP2 to an SRE motif in a 
genomic context, ChIP assays were performed with livers of WT and Cyp3a-/- mice. The Hmgcs1 
promoter contains a known SRE motif [41]. The specific binding of SREBP2 to the SRE-containing 
region (-348 to -208 bp) was significantly more abundant in the livers of Cyp3a-/- mice than in the 
livers of WT mice (P < 0.01, Fig. 5). The degree of binding of SREBP2 to the negative control region 
was low and showed no difference between WT and Cyp3a-/- mice. 
 
1-3-4. Effects of CYP3A deficiency on cholesterol biosynthesis 
 
Since transcription of genes encoding enzymes involved in cholesterol biosynthesis enhanced 
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in Cyp3a-/- mice, we examined total cholesterol levels in the plasma and livers, lathosterol levels in the 
plasma and 25-HC levels in the livers of WT and Cyp3a-/- mice. As shown in Table 3, body weight 
and liver weight of Cyp3a-/- mice were higher than those of WT mice. Total cholesterol levels in the 
livers of Cyp3a-/- mice were about 20% lower than those in the livers of WT mice (P < 0.05), although 
no significant difference was found in plasma total cholesterol levels between WT and Cyp3a-/- mice. 
Plasma lathosterol levels, as an indicator of cholesterol biosynthesis [42], showed a trend toward 
higher than those of WT mice, although the difference was not significant. 25-HC levels in the livers 
of Cyp3a-/- mice were significantly lower than those in the livers of WT mice (P < 0.05). 
 
1-3-5. Effects of CYP3A deficiency on expression levels of cholesterol transporters 
 
To investigate the mechanism of decreased hepatic total cholesterol in Cyp3a-/- mice, we 
determined the mRNA expression levels of genes involved in the influx and efflux of cholesterol. As 
shown in Fig. 6A, no significant differences in expression levels of ABCG5, ABCG8, ABCA1 and 
LDLR mRNAs in the liver were found between WT and Cyp3a-/- mice. As shown in Fig. 6B, 
expression levels of ABCG5, ABCG8 and ABCA1 mRNAs in the small intestine were also similar 
between WT and Cyp3a-/- mice. Expression levels of NPC1L1 mRNA in the small intestines of Cyp3a-
/- mice were 1.7-fold higher than those of WT mice. 
 
1-3-6. Effects of CYP3A deficiency on bile acid biosynthesis 
 
Synthesis and secretion of bile acids constitute a major route for elimination of cholesterol 
from the liver [31]. To determine the mechanism of reduction of hepatic cholesterol in Cyp3a-/- mice, 
we investigated expression levels of four enzymes involved in bile acid biosynthesis. The classical 
pathway of bile acid synthesis is initiated by 7α-hydroxylation of cholesterol catalyzed by CYP7A1, 
which is a rate-limiting enzyme of this pathway [31]. The next product C4 is metabolized to 7α, 12α-
dihydroxy-4-cholesten-3-one by CYP8B1. Then the resulting product is converted ultimately into bile 
acid [31]. An alternative pathway of bile acid synthesis is initiated by 27-hydroxylation of cholesterol 
catalyzed by CYP27A1 [31]. Subsequently, 27-HC is metabolized to 7α, 27-diHC by CYP7B1 and 
3β-hydroxy-5-cholestenoic acid by CYP27A1 [31]. As shown in Fig. 7, the expression levels of 
CYP7A1, CYP8B1 and CYP7B1 mRNAs were significantly higher in the livers of Cyp3a-/- mice than 
those of WT mice (1.9, 2.7 and 3.3 fold, respectively). Expression levels of CYP27A1 and SHP 
mRNAs in the liver were similar between WT and Cyp3a-/- mice. 
Since the expression levels of CYP7A1, CYP8B1 and CYP7B1 were higher in the livers of 
Cyp3a-/- mice compared with WT mice, we studied whether bile acid synthesis was enhanced in Cyp3a-
/- mice. As shown in Fig. 8A, plasma concentration of C4 was 1.6-fold higher in Cyp3a-/- mice than in 
WT mice (P < 0.05). As shown in Fig. 8B, total bile acid levels in the livers of Cyp3a-/- mice were also 
significantly higher than those of WT mice (P < 0.05). Bile acid pool size of Cyp3a-/- mice showed a 
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trend toward higher levels than those of WT mice, although differences were not significant (Fig. 8C). 
 
1-3-7. Effects of CYP3A deficiency on expression of target genes of PXR 
 
Since activated pregnane X receptor (PXR) could suppress transcription of mouse Cyp7a1 
gene [43, 44], we measured the mRNA expression levels of target genes of PXR in the livers of WT 
and Cyp3a-/- mice. The mRNA expression levels of Mdr1a in the livers of Cyp3a-/- mice were lower 
than those of WT mice, whereas expression levels of OATP2, SULT2A1, CYP2C55 and CYP2B10 
mRNAs in the livers of Cyp3a-/- mice were higher than those of WT mice (Fig. 9).  
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Table 3.  Body and liver weight, and plasma and hepatic levels of cholesterol and oxysterol in 
WT and Cyp3a-/- mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Genotype 
Parameter WT Cyp3a-/- 
Body weight (g) 23.7 ± 0.3 27.7 ± 1.1a 
Liver weight (g) 1.0 ± 0.03 1.5 ± 0.07b 
Plasma lathosterol (ng/mL) 32.1 ± 2.0 41.3 ± 7.9 
Plasma total cholesterol (mg/dL) 63.4 ± 9.8 82.6 ± 7.5 
Liver total cholesterol (mg/g) 2.8 ± 0.14 2.2 ± 0.03c 
Liver 25-HC (ng/g) 20.0 ± 1.4 14.9 ± 1.3c 
Different groups of animals were used for measurements of plasma lathosterol, plasma cholesterol, 
liver cholesterol and liver 25-HC. Data for body and liver weight represent the mean ± S. E. M. of 
nine mice in each group. Data for cholesterol and 25-HC levels are shown as means ± S. E. M. of 
three and six mice in each group, respectively. Data for lathosterol levels are expressed as a mean 
± S. D. of three independent determinations, using pooled plasma from six mice. aP < 0.01, bP < 
0.001 and cP < 0.05 versus WT mice 
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Fig. 2.  Expression levels of HMGCS1 (A), HMGCR (B) and SQLE (C) mRNAs in the livers 
of WT and Cyp3a-/- (KO) mice.  
Expression levels were normalized by those of GAPDH and are shown as means ± S. E. M. of six 
mice in each group. cDNAs prepared from each mouse were used for triplicate determination. **P 
< 0.01 versus WT mice. 
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Fig. 3.  Expression levels of HMGCS1 (A), HMGCR (B) SQLE (C) and SREBF2 (D) mRNAs 
in the intestines of WT and Cyp3a-/- (KO) mice. 
Expression levels were normalized by those of GAPDH and are shown as means ± S. E. M. of six 
mice in each group. cDNAs prepared from each mouse were used for triplicate determination. *P 
< 0.05 versus WT mice.  
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Fig. 4.  Expression levels of SREBP2 in the livers of WT and Cyp3a-/- (KO) mice.  
(A) Expression levels of SREBF2 mRNAs were normalized by those of GAPDH and are shown as 
means ± S. E. M. of six mice in each group. cDNAs prepared from each mouse were used for 
triplicate determination. ***P < 0.001 versus WT mice. (B) SREBP2 protein was assessed using 
Western blotting of isolated hepatic nuclear protein. TBP was used as a loading control. 
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Fig. 5.  SREBP2 binding to Hmgcs1 promoter (-348 to -208) in the livers of WT and Cyp3a-/- 
(KO) mice. 
ChIP assay was performed using anti-SREBP2 antibody. Liver tissues from two mice in each group 
were pooled and subjected to the assay. The immunoprecipitated DNA, along with the DNA isolated 
before immunoprecipitation (Input), were analyzed by semi-quantitative PCR (A) and quantitative 
PCR (B). Signals were normalized to input DNA. Data are means ± S.D. of three independent 
determinations, each performed in duplicate. **P < 0.01 versus WT mice. 
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Fig. 6.  Expression levels of ABCG5, ABCG8, ABCA1, LDLR and NPC1L1 mRNAs in the 
livers (A) and intestines (B) of WT and Cyp3a-/- (KO) mice. 
Expression levels were normalized by those of GAPDH and are shown as means ± S. E. M. of six 
mice in each group. cDNAs prepared from each mouse were used for triplicate determination. *P 
< 0.05 versus WT mice. 
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Fig. 7.  Expression levels of CYP7A1 (A), CYP8B1 (B), CYP27A1 (C), CYP7B1 (D) and SHP 
(E) mRNAs in the livers of WT and Cyp3a-/- (KO) mice. 
Expression levels were normalized by those of GAPDH and are shown as means ± S. E. M. of six 
mice in each group. cDNAs prepared from each mouse were used for triplicate determination. **P 
< 0.01 and ***P < 0.001 versus WT mice. 
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Fig. 8.  Concentration of C4 in plasma (A), hepatic bile acid (B) and bile acid pool size (C) 
of WT and Cyp3a-/- (KO) mice. 
Plasma C4 concentrations are expressed as a mean ± S. D. of triplicate determinations, using pooled 
plasma from six mice. Hepatic bile acid levels were expressed as means ± S. E. M. of three mice in 
each group. Bile acid pool size was determined as total bile acid from liver, gallbladder and 
intestine. The values of bile acid pool size were shown as means ± S. E. M. of three mice in each 
group. *P < 0.05 versus WT mice. 
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Fig. 9.  Expression levels of OATP2 (A), SULT2A1 (B), CYP2C55 (C), CYP2B10 (D) and 
Mdr1a (E) mRNAs in the livers of WT and Cyp3a-/- (KO) mice. 
Expression levels were normalized by those of GAPDH and are shown as means ± S. E. M. of six 
mice in each group. cDNAs prepared from each mouse were used for triplicate determination. *P 
< 0.05, **P < 0.01 and ***P < 0.001 versus WT mice. 
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1-4. Discussion 
 
In this study, we showed for the first time that mRNA expression levels of enzymes (i.e., 
HMGCS1 and SQLE) involved in cholesterol biosynthesis were higher in the livers of Cyp3a-/- mice 
than in the livers of WT mice (Fig. 2). We also found that expression levels of SREBP2, which 
activates the transcription of these genes [8, 26], were increased in the livers of Cyp3a-/- mice compared 
with those in the livers of WT mice at the levels of mRNA and nuclear protein (Fig. 4). In addition, 
results of the ChIP assay showed that binding of SREBP2 to the promoter region of the Hmgcs1 gene 
was greater in the livers of Cyp3a-/- mice than in the livers of WT mice (Fig. 5). These results clearly 
indicated that SREBP2 was activated in the livers of Cyp3a-/- mice, resulting in enhancing transcription 
of genes encoding enzymes involved in cholesterol biosynthesis. Furthermore, plasma levels of 
lathosterol in Cyp3a-/- mice showed a trend toward higher than those of WT mice, although the 
difference was not significant (Table 3). Therefore, deficiency of CYP3A enzymes may increase 
cholesterol synthesis.  
Despite the fact that cholesterol biosynthesis was activated in Cyp3a-/- mice, total cholesterol 
levels in the liver were decreased in Cyp3a-/- mice compared with those in WT mice (Table 3). Since 
hepatic cholesterol levels are regulated by influx, efflux and conversion into bile acids of cholesterol, 
we investigated mRNA expression levels of cholesterol transporters and a rate-limiting enzyme in bile 
acid biosynthesis in WT and Cyp3a-/- mice. Results of the present study showed that deficiency of 
CYP3A enzymes did not affect mRNA expression levels of ABCG5, ABCG8, ABCA1 and LDLR in 
the liver (Fig. 6A). In the intestine, mRNA expression levels of ABCG5, ABCG8 and ABCA1 were 
similar between WT and Cyp3a-/- mice, and deficiency of CYP3A enzymes did not decrease mRNA 
levels of cholesterol influx transporter NPC1L1 (Fig. 6B). On the other hand, mRNA levels of 
CYP7A1, CYP8B1 and CYP7B1 were significantly higher in Cyp3a-/- mice than in WT mice (Fig. 7). 
Plasma concentration of C4 and total bile acid levels in the liver were also significantly higher in 
Cyp3a-/- mice than in WT mice (Figs. 8A and 8B). Therefore, it is thought that reduction of hepatic 
total cholesterol in Cyp3a-/- mice was due to enhanced bile acid synthesis rather than alteration in 
cholesterol transport in the intestine and liver. This idea is supported by results of a previous study 
showing that hepatic total cholesterol in rat CYP7A1 transgenic hamsters maintained on a western-
type diet was decreased because of enhancement of bile acid synthesis [45]. Conversely, CYP7A1 
mutation, which leads to loss of active sites and function, resulted in suppression of the classical 
pathway of bile acid synthesis and substantial cholesterol accumulation in the human liver [46]. These 
findings suggest that reduction of hepatic total cholesterol in Cyp3a-/- mice would be the consequence 
of enhanced bile acid synthesis by CYP7A1, CYP8B1 and CYP7B1.  
In this study, we found that deficiency of CYP3A enzymes enhanced expression of CYP7A1 
and CYP8B1 (Figs. 7A and 7B). It is well known that Cyp7a1 gene is transcriptionally activated by 
liver X receptor α (LXRα) [47]. However, no difference between WT and Cyp3a-/- mice was observed 
in the expression levels of ABCG5, ABCG8 and ABCA1, which were typical target genes of LXRα 
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(Fig. 6) [27, 48]. Therefore, it was not suggested that deficiency of CYP3A enzymes was involved in 
the activation of LXRα. Expression of CYP7A1 and CYP8B1 is regulated by farnesoid X receptor 
(FXR), which suppresses the transcription of genes through activation of SHP [49, 50]. However, 
deficiency of CYP3A enzymes did not affect the expression of SHP mRNA (Fig. 7E). Expression of 
CYP7A1 is also suppressed through activation of PXR [43, 44]. If deficiency of CYP3A enzymes 
could lead to deactivation of PXR through decreased formation of PXR ligands, expression of 
CYP7A1 might be increased. However, deficiency of CYP3A enzymes increased the expression of 
four target genes of PXR except for Mdr1 (Fig. 9). Therefore, it is hard to consider that PXR were 
deactivated in the livers of Cyp3a-/- mice compared with those of WT mice. Taken together with these 
findings, enhanced expression of CYP7A1 and CYP8B1 in Cyp3a-/- mice may be regulated by factors 
except for LXRα, FXR and PXR. Further studies are needed to clarify the mechanism. 
Several studies have shown that CYP3A enzymes are involved in cholesterol metabolism. It 
has been reported that CYP3A enzymes catalyze 4βHC and 25HC of cholesterol [5, 6]. 4β-HC was 
recently shown as an LXR activator [51], whereas its role in the cholesterol synthesis is unclear. On 
the other hand, 25HC is well known as a negative regulator in the cholesterol synthesis [35]. 25HC 
and other oxysterols suppress cholesterol biosynthesis by suppressing proteolytic activation of 
SREBP2 [35]. Although production of 25-HC is also produced by microsomal cholesterol 25-
hydroxylase [10], mitochondrial CYP27A1 [11, 12] and non-enzymatic autoxidation of cholesterol 
[13], results of the present study showed that levels of 25-HC in the livers of Cyp3a-/- mice were 
significantly lower than those in WT mice (Table 3). Therefore, it is suggested that deficiency of 
CYP3A lead to reduction of 25HC synthesis, resulting in activation of SREBP2. 
25HC is metabolized to 7α, 25-diHC by CYP7A1 and CYP7B1 [52]. Results of the present 
study showed that the expression of CYP7A1 and CYP7B1 in the livers of Cyp3a-/- mice were higher 
than those of WT mice (Fig. 7). Therefore, up-regulation of these genes may also relate to the reduction 
of 25HC and the activation of SREBP2 in the livers of Cyp3a-/- mice. In addition, it is possible that 
deficiency of CYP3A enzymes enhanced bile acid synthesis with consumption of cholesterol in the 
liver, resulting in compensatory up-regulation of cholesterol synthesis.  
Interestingly, it has been reported that mice fed a 25-HC containing diet (0.25%) show 
decreased body weight relative to control mice fed the basal diet [53]. In this study, deficiency of 
CYP3A enzymes caused increase of body and liver weight (Table. 3). Taken together, decreased 
oxysterols appear to increase body and liver weight of Cyp3a-/- mice, although the mechanism is 
unclear. 
Activated SREBP2 up-regulates the expression of numbers of genes involved in cholesterol 
synthesis and uptake. However, there are large differences in the effects of SREBP2 on the expression 
of mRNA [54]. Therefore, no change of the expression of LDLR mRNA in the livers of Cyp3a-/- mice 
may be due to the small response to SREBP2 activation. 
The results of the present study showed that SREBP2 is activated in the livers of Cyp3a-/- mice 
possibly due to reduction of the formation of 25-hydrxy-cholesterol and/or other cholesterol 
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metabolites, which may result in enhancement of the transcription of genes encoding enzymes 
involved in cholesterol biosynthesis. Interestingly, it has been reported that feeding a low-cholesterol 
diet to mice attenuates hepatic CYP3A11 expression by activating hepatic SREBP2 [55]. Activated 
SREBP2 has been suggested to interact with peroxisome proliferator-activated receptor γ coactivator-
1α (PGC-1α) in the mouse liver, resulting in reduced PGC-1α recruitment to hepatocyte nuclear factor-
4α on the CYP3A11 promoter and subsequent down-regulation of CYP3A11 expression [55]. 
Conversely, feeding high-cholesterol diets to rats has been reported to increase expression and activity 
of CYP3A [56]. Similarly, a cholesterol and cholic acid-supplemented diet increased mRNA 
expression levels of mouse CYP3A11 [57]. These findings are considered to be important, being 
coupled with the findings in the present study that transcription of genes encoding enzymes responsible 
for the synthesis of cholesterol was enhanced by activation of SREBP2 in Cyp3a-/- mice. We are 
tempted to speculate that in the environment of a low-cholesterol diet, CYP3A enzymes are down-
regulated, and down-regulated CYP3A enzymes attenuate the formation of oxysterols such as 25-HC. 
This reduction of oxysterols would activate SREBP2 and enhance expression of genes encoding 
enzymes involved in cholesterol biosynthesis, which may increase hepatic cholesterol biosynthesis to 
restore cholesterol levels. In the environment of a high-cholesterol diet, a reverse phenomenon may 
occur. Thus, CYP3A enzymes may play an important role in maintaining a constant level of hepatic 
cholesterol, irrespective of environmental changes in dietary cholesterol. However, this is only a 
hypothesis. Further studies are needed to clarify the role of CYP3A enzymes in the homeostasis of 
cholesterol in the liver. 
In summary, the results of the present study showed that expression of genes encoding 
enzymes involved in cholesterol biosynthesis is enhanced via the activation of SREBP2 in the livers 
of Cyp3a-/- mice, possibly due to the decreased formation of oxysterols. Since dietary cholesterol has 
been reported to affect gene expression of CYP3A enzymes [55-57], the present observations suggest 
that CYP3A enzymes play a role in maintaining cholesterol levels at a constant level in the liver. The 
results of the present study also showed that total cholesterol levels were also decreased by 20% in the 
livers of Cyp3a-/- mice, possibly due to enhanced bile acid synthesis by elevation of CYP7A1 in Cyp3a-
/- mice. Further studies are required to clarify the role of CYP3A enzymes in the homeostasis of 
cholesterol in the liver.  
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Chapter Ⅱ 
Studies on the effects of Cyp3a deficiency on  
AR activity and cholesterol synthesis in prostate 
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2-1. Introduction 
Androgens play critical roles in several stages of development and maintenance of the prostate 
through activation of AR. Testosterone is a principal androgen that circulates in the bloodstream largely 
bound to sex hormone–binding globulin (SHBG) and diffuses into a target organ as a free form of 
testosterone [58]. In the prostate, testosterone is converted by steroid 5α-reductase 2 (SRD5A2) into 
dihydrotestosterone (DHT), having higher affinity than testosterone to the AR, and activates the AR. 
The activated AR translocates from the cytoplasm to the nucleus, dimerizes, binds to the androgen 
response element (ARE) in the genome sequences of target genes, and regulates their transcription. 
Testosterone is inactivated through hydroxylation and conjugation pathways [59, 60]. 6β-
Hydroxylation is the main pathway among testosterone hydroxylation processes in the liver microsome. 
Testosterone 6β-hydroxylation is mainly catalyzed by CYP3A [7, 61], which is expressed in the liver 
predominantly and is also expressed in other organs including the prostate [62-65]. Recently, Zhang et 
al. [18] reported that treatment with pregnenolone 16α-carbonitrile, an inducer of CYP3A, reduces 
either the plasma testosterone levels or prostate weights in castrated mice. This finding suggests that 
CYP3A is one of the regulators for circulating testosterone and its effects on the prostate [14]. However, 
it remains unclear whether a decreased state of CYP3A activity affects the systemic level of 
testosterone and its effects on the prostate. 
Androgens enhance cholesterol synthesis in the LNCaP line of cells, an androgen-dependent 
prostate cancer cell line, by the following mechanism: androgens stimulate the processing of SREBP2 
through AR-mediated activation of SCAP gene transcription [11, 12], and activated SREBP2 increases 
expression levels of genes involved in the synthesis and transport of cholesterol such as Hmgcs1, 
Hmgcr, and Ldlr [8]. However, whether androgens stimulate these processes in the in vivo prostate 
remains unclear.  
The purpose of the present study was to clarify whether a reduced state of CYP3A activity 
affects the systemic levels of testosterone and its effect on the prostate. To accomplish this purpose, 
we studied the effects of Cyp3a deficiency on circulating testosterone levels and prostatic expression 
levels of genes regulated by the AR using Cyp3a-knockout (Cyp3a-/-) mice. We also studied the 
expression levels of genes involved in cholesterol synthesis and total cholesterol content in the prostate 
of Cyp3a-/- mice in order to explore the possibility that activation of the AR affects cholesterol 
synthesis via the SCAP-SREBP2 pathway in the prostate.   
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2-2. Materials and Methods 
 
2-2-1. Chemicals 
 
Testosterone and formaldehyde were purchased from Wako. 6βHT was purchased from 
Sigma-Aldrich. Bicalutamide was purchased from Tokyo Chemical Industry (Tokyo, Japan). High-
performance liquid chromatography (HPLC) grade acetonitrile, chloroform and methanol purchased 
from Wako were also used in our experiments. 
 
2-2-2. Animals 
 
We previously reported the generation of Cyp3a-/- mice that lacked six Cyp3a isoforms 
(Cyp3a13/57/44/11/25/59) [33]. Briefly, conventional gene targeting and Cre-loxP-mediated 
chromosomal deletion were, respectively, used to generate Cyp3a13-/- and Cyp3a57-59-/- lines, after 
which the two lines were mated to generate Cyp3a-/- mice. The size between the Cyp3a57-59 gene 
cluster and a Cyp3a13 gene is ~5 Mb, and several genes are located between the loci, so the two 
knockout lines were generated independently. The generated Cyp3a-/- mice were backcrossed to 
C57BL/6JJcl mice (CLEA) more than five-generation. The deficiency of mRNA expression of the six 
Cyp3a isoforms in the livers and prostates of Cyp3a-/- mice was then confirmed [33] (Fig. 10). In these 
studies, C57BL/6JJcl mice were used as WT mice.  
All experiments were performed using male mice between 10 and 11 weeks of age, and all 
experimental animals were kept in a temperature-controlled environment with a 12-hr light/dark cycle. 
The light-cycle hours were between 7 AM and 7 PM. The mice weighting 23.3 ± 0.18 g for WT mice 
and 23.5 ± 0.43 g for Cyp3a-/- mice received a chow diet containing 0.1% cholesterol (CE-2, CLEA). 
The mice were sacrificed between 10 and 11 AM without a prior fast. The plasma, livers, and total 
prostates (including the anterior, ventral, lateral, and dorsal prostate lobes) were collected immediately 
and stored at -80ºC until usage. The present study was conducted in accordance with the Guidelines 
for the Care and Use of Laboratory Animals, as adopted by the Committee on Animal Research of 
Tottori University and Chiba University.  
 
2-2-3. Treatment with bicalutamide 
 
Male Cyp3a-/- mice were 10 weeks of age at the time of drug administration. Bicalutamide 
was formulated in polyethylene glycol 400 (PEG400)/Tween 80 (80:20 by volume) and administered 
orally by gavage once per day in 10 mg/kg for 7 days. A control group was administered the vehicle 
daily. Prostate samples were frozen at -80℃ until analysis. 
 
2-2-4. RNA isolation and cDNA synthesis 
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Total RNA was isolated from prostate and liver tissues, extracted using ISOGEN (Nippon 
Gene), and then purified using RNeasy columns (Qiagen) in accordance with the manufacturer’s 
instructions. All specimens were then treated with RNase-free DNase I (Wako). The cDNA was 
generated with a random hexamer using a High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). 
 
2-2-5. Analysis of mRNA levels 
 
Expression levels of Cyp3a11/13/16/25/57/59 were determined by semi-quantitative 
polymerase chain reaction (PCR) analysis as described previously [66]. The primer sequences used to 
amplify Cyp3a11/13/16/25/57/59, Hmgcs1, Hmgcr, Ldlr and Srebf2 have been described previously 
[33, 66]. Specific primers for D-dopachrome tautomerase (Ddt), protein kinase C delta (Prkcd), 
spermine-binding protein (Sbp) and Scap are listed in Table 4. Expression levels were measured by 
SYBR Green-based real-time PCR using KAPA SYBR Fast ABI Prism 1000 (KAPA Biosystems, 
Woburn, MA) carried out on an EcoReal-time PCR system (Illumina). The mRNA expression levels 
were normalized using 18S rRNA as an endogenous control gene. 
 
2-2-6. Preparation of liver microsomes 
 
Liver tissues were homogenized in ice-cold 1.15% KCl and microsomes were isolated by 
differential centrifugation. Briefly, liver homogenate was centrifuged at 9000 × g for 20 min at 4ºC. 
The resultant supernatant was then ultra-centrifuged at 105,000 × g for 1 h at 4ºC. The microsomal 
pellet was then washed and resuspended in 100 mM sodium phosphate buffer (pH 7.4) and stored at 
−80ºC until analysis. Protein concentrations were determined using a DC protein assay kit (Bio-Rad) 
according to manufacturer’s instructions. 
 
2-2-7. Enzyme assay 
 
Testosterone 6β-hydroxylase activity was determined as described previously with some 
modifications [67]. Briefly, the basic incubation mixture contained 0.05 mg/ml liver microsomes, 0.1 
mM EDTA, 100 mM potassium phosphate buffer (pH 7.4), an NADPH-generating system (0.5 mM 
NADP+, 2 mM glucose-6-phosphate, 1 IU/ml glucose-6-phosphate dehydrogenase, 4 mM MgCl2) and 
a substrate (30 μM testosterone), in a final volume of 250 μl. The mixtures were preincubated for 1 
min at 37ºC, and reactions were initiated by the addition of 25 μl of the NADPH-generating system. 
After 45 min, incubation was stopped by the addition of 100 μl of acetonitrile, followed by the addition 
of 50 μl of 1 μg/ml diazepam in methanol as an internal standard. Next, the incubated solution was 
mixed with 500 μl of acetonitrile and 300 μl of 3 M NaCl and then centrifuged at 1000 × g for 15 min, 
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after which 400 μl of the supernatant (organic layer) was transferred to a new tube and dried under 
vacuum conditions. The residue was reconstituted with 300 μl of a mobile phase consisting of 10 mM 
potassium phosphate buffer (pH 7.4) and methanol (2/3, v/v) with a flow rate of 0.9 ml/min. In the 
next step, an aliquot containing 100 μl of the reconstituted sample was subjected to HPLC analysis 
using a Hitachi L-7000 model HPLC system (Tokyo, Japan) consisting of an L-7400 UV detector and 
a CAPCELL PAK C18 UG120 column (4.6 mm × 250 mm, 5 mm; Shiseido, Tokyo, Japan). The eluent 
was monitored at a wavelength of 245 nm. 
 
2-2-8. Preparation of whole cell lysate 
 
Pooled prostate tissues (20 mg) from six mice were homogenized by mashing with a micro 
homogenizer pastle in 100 μl of lysis buffer [20 mM Hepes, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM 
EDTA and 1% (v/v) NP40 supplemented with 1 mM PMSF and 0.1% (v/v) proteinase inhibitor cocktail 
(Merck Millipore, Billerica, MA)], incubated for 30 min at 4ºC, and then centrifuged at 14000 × g for 
5 min at 4ºC. The supernatants were then transferred to new tubes and stored at −80ºC until used. 
Protein concentrations were determined using a DC protein assay kit (Bio-Rad) according to the 
manufacturer’s instructions. 
 
2-2-9. Western blot analysis 
 
Whole cell lysates (20 μg/lane) were separated by SDS-polyacrylamide gel electrophoresis 
and transferred to a nitrocellulose membrane. After 1-hr incubation with blocking buffer (0.05% 
Tween 20 in phosphate buffered saline (PBS) containing 5% skim milk), the membrane was probed 
for 1 hr at room temperature using an anti-SCAP goat antibody (1:200 dilution, sc-9675, Santa Cruz 
Biotechnology) and an anti-SREBP2 rabbit antibody (1:200 dilution, ab30682, Abcam). An anti-β-
actin mouse antibody (1:5,000 dilution, Sigma-Aldrich) and an anti-GAPDH rabbit antibody (1:2,000 
dilution, Sigma-Aldrich) were used as an internal control. After washing, the membrane was incubated 
with a peroxidase-conjugated secondary antibody for 1 hr at room temperature. The secondary 
antibodies used were an anti-rabbit IgG (1:50,000 dilution, Sigma-Aldrich), an anti-mouse IgG 
(1:50,000 dilution, Abcam) and an anti-goat IgG (1:20,000 dilution, Sigma-Aldrich). The anti-SCAP, 
anti-β-actin and anti-GAPDH antibodies were diluted with 0.05% Tween 20 in PBS containing 3% 
bovine serum albumin (BSA). The anti-SREBP2 antibody was diluted with Can Get Signal Solution 1 
(TOYOBO, Osaka, Japan). Protein bands were visualized via ECL Western Blotting Detection 
Reagents (GE Healthcare) and ImmunoStar LD (Wako) using LAS-4000 (GE healthcare) and 
quantified by ImageQuant TL (ver. 8.1, GE Healthcare).  
 
2-2-10. ChIP assay 
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A ChIP assay was conducted as described previously [66]. In brief, pooled prostate tissues 
(60 mg) from six mice were minced and fixed by 1% formaldehyde, after which the extracted nuclei 
were immunoprecipitated with polyclonal anti-AR rabbit antibody (sc-816, Santa Cruz) or rabbit IgG-
ChIP grade (ab37415, Abcam). DNA samples were measured by real-time PCR using SYBR Green-
based real-time PCR with KAPA SYBR Fast ABI Prism 1000 (KAPA Biosystems). PCR was carried 
out with primers encompassing the region containing the ARE site (-539 bp to -438 bp in Sbp promoter 
and -209 bp to -102 bp in Prkcd promoter) and the non-specific region (+11,862 bp to +11,948 bp in 
Sbp gene) as a negative control. The PCR conditions for Sbp promoter were one cycle of pre-
denaturation at 95°C for 10 min, 45 cycles of denaturation at 95°C for 15 sec, annealing at 58°C for 
30 sec, and elongation at 72°C for 15 sec. The PCR conditions for Prkcd promoter were one cycle of 
pre-denaturation at 95°C for 10 min, 45 cycles of denaturation at 95°C for 15 sec, annealing and 
elongation at 60°C for 30 sec. The primers used are as follows: Sbp/ARE, 5’- 
CCCAGTATAGCATCATCATCAACA-3’ and 5’-AAATGCTGGAACTACCTGTGAATC-3’: 
Prkcd/ARE, 5’-GCCAGCAGGAAGAGGAATGA-3’ and 5’-GGCTTCCCCAACTACTTGCG-3’: 
Sbp/negative control, 5’-GGACACTTCTGGAGCCTGAACT-3’ and 5’- 
AGCTGGAAGCTGGAGAGAAATC-3’. 
 
2-2-11. Analysis of testosterone and DHT levels 
Hepatic total testosterone levels were determined by HPLC. Pooled liver tissue (600 mg) from 
six mice was homogenized in 1 ml of PBS (-) and mixed with 10 μl of 1 μg/ml diazepam as an internal 
standard. Next, the homogenates were extracted with 20 μl of 2 M sodium hydroxide and 5 ml of 
chloroform. The mixture was vigorously mixed for 1 min and then centrifuged at 2000 × g for 15 min. 
The organic layer was then transferred to a new tube and dried under vacuum conditions. The residue 
was resolved with 200 μl of mobile phase. One hundred μl of the reconstituted sample was analyzed 
by an HPLC system as described in the enzyme assay section, except that the mobile phase consisted 
of 10 mM potassium phosphate buffer (pH 7.4) and methanol (37/63, v/v).  
Total plasma and prostatic testosterone levels and free plasma testosterone levels were 
measured using a Free Testosterone ELISA Kit (Cusabio Biotech, Hubei, China). To analyze total 
testosterone levels, 10 μl of pooled plasma and 15 mg of pooled prostates from six mice was extracted 
as described above. The organic layer was dried under vacuum conditions and resolved with 2.5 μl of 
ethanol and sterilized water 400 μl for plasma or 180 μl for prostates. Free testosterone levels in plasma 
were then measured without extraction. Next, 50 μl of extracts from plasma and prostates, and 50 d 
prosnon-extracted plasma were used for total plasma and prostatic testosterone, and free plasma 
testosterone determination, respectively, according to the manufacturer’s instructions. DHT levels in 
the prostates were measured using a DHT ELISA kit (Cusabio Biotech). Pooled prostates were 
extracted as described for the testosterone and 50 μl of the extracts were used for determination of 
DHT levels, according to the manufacturer’s instructions. The manufacturer’s specifications state that 
these ELISA assays are highly specific and that there is no significant cross-reactivity or interference 
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with their analogues. 
 
2-2-12. Analysis of cholesterol levels  
 
The concentration of total cholesterol in the prostate was determined using a Cholesterol E-
Test Wako kit (Wako) according to the manufacturer’s instructions. Pooled prostate tissue from each 
of the six mice was used. Prostatic lipids were extracted according to the procedure described in our 
previous report [66] and then reconstituted in 4% methanol. 
 
2-2-13. Statistical analysis 
 
The number of mice in each group is shown in the legends of figures. Data are shown as 
means ± S. E. M. or S. D. as described in each figure legend. Statistical analyses were performed by 
using Statcel (OMS, Saitama, Japan). Comparisons were made with Student’s t-test or Welche’s t-test. 
P < 0.05 was considered statistically significant. 
 
Table 4. Oligonucleotide primers used in real-time PCR 
Name Direction Sequence (5’ to 3’) 
DDT Forward 
Reverse 
ACAGCCACCATCCTGGACAA 
CCAGAAGGTGAGCACAAGGC 
PRKCD  Forward 
Reverse 
GATGAAGGAGGCACTCAGCA  
CGCATCAGCACAATCTGGAT 
SBP Forward 
Reverse 
GTGTTTTCAAGTTCATCAAGGGC 
GGGTTCCATAGACATCAGTCCA 
SCAP Forward 
Reverse 
CTGCGCATCCTATCCAATTC 
AGAATTCCACAGGTCCCGTT 
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Fig. 10. Expression of Cyp3a isoforms in prostates. 
A) Expression levels of mouse Cyp3a isoforms in livers and prostates of WT mice (n = 6) were 
analyzed by semi-quantitative RT-PCR. Total RNA (1 μg) extracted from each mouse was 
subjected to reverse transcription. The aliquots of cDNA products were pooled and diluted for 
amplification (36 times for liver, 36 and 3 times for prostate). B) Expression levels of mouse Cyp3a 
isoforms in prostates of WT and Cyp3a-/- (KO) mice (n = 6) were analyzed by semi-quantitative 
RT-PCR. Pooled prostate cDNA products were diluted 3 times and subjected to the assay. NC, 
negative control. 
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2-3. Results 
 
2-3-1. Effects of Cyp3a deficiency on testosterone 6β-hydroxylation 
 
6β-Hydroxylation activities for testosterone were measured in the liver microsomes of Cyp3a-
/- and WT mice. As shown in Fig. 11, the activity of Cyp3a-/- mice was 75% lower than that of WT 
mice (0.25 vs. 1.00 nmol/mg protein/min), whereas activities of testosterone hydroxylation at the other 
positions showed no significant difference between WT and Cyp3a-/- mice (data not shown). We also 
measured the activities in prostate microsomes of Cyp3a-/- and WT mice. However, activities were 
undetectable in prostate microsomes of Cyp3a-/- and WT mice (lower than detection limit, 0.067 
nmol/mg protein/min).  
 
2-3-2. Effects of Cyp3a deficiency on testosterone levels 
 
Total testosterone levels in the plasma and liver of Cyp3a-/- and WT mice were examined. As 
shown in Figs. 12A and 12B, the levels in the livers and plasma of Cyp3a-/- mice were 1.8-fold higher 
than those in the plasma and liver of WT mice (1.50 vs. 0.81 ng/g tissue and 590 vs. 334 pg/ml, 
respectively). Furthermore, free testosterone levels in the plasma of Cyp3a-/- mice were 9.0-fold higher 
than that in WT mice (218 vs. 24.3 pg/ml, Fig. 12B), although there was no significant difference 
between them in plasma levels of luteinizing hormone, which is a suppressor of testosterone synthesis 
(data not shown). As shown in Fig. 12C and 12D, total testosterone and DHT levels in the prostates 
were also 3.3-fold and 1.8-fold higher in Cyp3a-/- mice than that in WT mice, respectively (1.66 vs. 
0.51 ng/g tissue, and 0.72 vs. 0.39 ng/g tissue, respectively). In addition, mRNA expression levels of 
SRD5A2 were also higher in the prostates of Cyp3a-/- mice (Fig. 12E). Noting, Cyp3a-/- and WT mice 
used in this study showed no significant difference in prostate weight (data not shown). 
 
2-3-3. Effect of Cyp3a deficiency on androgen response 
 
Since increased levels of total testosterone in the prostates of Cyp3a-/- mice implies activation 
of androgen response in the prostates of Cyp3a-/- mice, we measured the expression levels of AR target 
genes. As shown in Fig. 13A, mRNA expression levels of Sbp, Prkcd, Ddt and Scap were significantly 
higher in the prostates of Cyp3a-/- mice than in the prostates of WT mice. In addition, protein 
expression levels of SCAP were higher in the prostates of Cyp3a-/- mice than those of WT mice (Fig. 
13B). Moreover, results of the ChIP assays showed that specific binding of the AR to the ARE-
containing region of the Sbp and Prkcd promoter [68, 69] was significantly more abundant in the 
prostates of Cyp3a-/- mice than in the prostates of WT mice (P < 0.01, Fig. 13C). The degree of binding 
of the AR to the non-specific region was low and showed no difference between Cyp3a-/- and WT mice.  
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2-3-4. Effects of Cyp3a deficiency on mRNA expression levels of target genes of SREBP2 and 
cholesterol contents in the prostate 
 
Since mRNA expression levels of Scap were elevated in the prostates of Cyp3a-/- mice, we 
determined whether SREBP2 was activated. As shown in Fig. 14A, protein expression levels of mature 
SREBP2, an active form, were higher in the prostates of Cyp3a-/- mice than those of WT mice. Next, 
we examined expression levels of target genes involved in the synthesis and transport of cholesterol. 
As shown in Fig. 14B, mRNA expression levels of Hmgcr, Hmgcs1 and Srebf2 were significantly 
higher in the prostates of Cyp3a-/- mice than in the prostates of WT mice. The expression levels of Ldlr 
were also higher in the prostates of Cyp3a-/- mice than in the prostates of WT mice, although the 
difference was not significant. Finally, total cholesterol levels were higher in the prostates of Cyp3a-/- 
mice than in the prostates of WT mice (Fig. 14C).  
 
2-3-5. Effects of bicalutamide treatment on mRNA expression levels of target genes of AR and 
SREBP2 in the prostate of Cyp3a-/- mice 
 
 To confirm the activation of AR and sequential activation of SREBP2 in the prostates of 
Cyp3a-/- mice, we examined whether treatment of bicalutamide, antiandrogen drug [70], reduced the 
mRNA expression levels of target genes of AR and SREBP2 in the prostates of Cyp3a-/- mice. As 
shown in Fig. 15, mRNA expression levels of target genes of AR and SREBP2 in the prostates were 
lower in the Cyp3a-/- mice treated with bicalutamide than those treated with the vehicle alone. Noting, 
bicalutamide treatment to WT mice reduced total cholesterol levels in the prostates (0.13 ± 0.02 vs. 
0.09 ± 0.01 mg/g tissue, P < 0.05), but not in the livers.  
 
Fig. 11. Testosterone 6β-hydroxylation activities in liver microsomes of WT and Cyp3a-/-(KO) 
mice. 
Testosterone (30 μM) was incubated with liver microsomes of WT and KO mice. Data are shown as 
means ± S. E. M (n = 5) of three independent determinations, each performed in duplicate. ***P < 
0.001 versus WT mice. 
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Fig. 12. Androgen levels and mRNA expression levels of Srd5a2 in WT and Cyp3a-/- (KO) mice. 
A) Levels of total hepatic testosterone in WT and KO mice were determined by HPLC using pooled 
liver tissue from six mice. B) Levels of total and free plasma testosterone in WT and KO mice were 
determined by ELISA using pooled plasma from six mice with or without extraction, respectively. C 
and D) Levels of total prostatic testosterone and DHT in WT and KO were measured by ELISA using 
pooled prostates from six mice. Data are shown as means ± S.D. of triplicate determination. E) The 
mRNA expression of Srd5a2 were determined and normalized by the expression levels of 18S rRNA. 
Data are shown as means ± S. E. M. (n = 6) of three independent determinations, each performed in 
duplicate. *P < 0.05, **P < 0.01, ***P < 0.001 versus WT mice. 
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Fig. 13. Expression levels of AR target genes in mRNA (A) and protein (B) and AR binding to 
Sbp and Prkcd promoter (C) in the prostates of WT and Cyp3a-/- (KO) mice 
A) The mRNA expression levels were normalized by expression levels of 18S rRNA. Data are shown 
as means ± S. E. M. (n = 6) of three independent determinations, each performed in duplicate. B) SCAP 
protein was assessed by Western blot analysis using pooled lysate of prostates from six mice. β-Actin 
were used as a loading control. C) ChIP assays were performed using anti-AR antibody. Prostate tissues 
from five mice in each group were pooled and subjected to the assay. The immunoprecipitated DNA 
along with the DNA isolated before immunoprecipitation (input) were analyzed by quantitative PCR. 
Signals were normalized by input DNA. Data are shown as means ± S.D. of triplicate determination. 
*P < 0.05 and **P < 0.01 versus WT mice. 
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Fig. 14. Protein expression levels of SREBP2 (A), mRNA expression levels of SREBP2 target 
genes (B) and total cholesterol contents (C) in prostates of WT and Cyp3a-/- (KO) mice. 
A) Expression levels of mature SREBP2 were studied by Western blot analysis using pooled lysate of 
prostates from six mice. GAPDH were used as a loading control. B) The mRNA expression levels 
were normalized by expression levels of 18S rRNA. Data are shown as means ± S. E. M. (n = 6) of 
three independent determinations, each performed in duplicate. B) Total cholesterol levels in prostates 
were measured using pooled tissue from five mice. Data for total cholesterol contents in prostates 
represent the mean ± S. D. of triplicate determination. *P < 0.05, **P < 0.01 and ***P < 0.001 versus 
WT mice. 
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Fig. 15. Effects of bicalutamide treatment on mRNA expression levels of target genes of AR (A) 
and SREBP2 (B) in the prostates of Cyp3a-/- mice. 
Cyp3a-/-mice were orally treated with bicalutamide (10mg/kg/day, closed bars) or vehicle alone (striped 
bars) for 7 days. The mRNA expression levels were normalized by expression levels of 18S rRNA. 
Data are shown as means ± S. E. M. (n = 3) of three independent determinations, each performed in 
duplicate. *P < 0.05, **P < 0.01 and ***P < 0.001 versus Cyp3a-/- treated with vehicle. 
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2-4. Discussion 
 
A previous report using Cyp3a-/- mice has shown that Cyp3a deficiency impaired drug 
metabolism dramatically [15]. We recently showed that hepatic cholesterol and bile acid synthesis 
were enhanced in the liver of Cyp3a-/- mice [66]. Thus, Cyp3a-/- mice are useful tools to clarify 
pharmacological and physiological role of CYP3A in vivo.  
The results of the present study showed that 6β-hydroxylation activities of testosterone were 
remarkably decreased in the liver microsomes of Cyp3a-/- mice, being consistent with the results of 
previous studies showing that inactivation of testosterone into 6βHT in the liver is mainly catalyzed 
by CYP3A [7, 60]. Since the liver is considered to be the most important organ responsible for the 
catabolism of steroid hormones [13], the in vitro findings are consistent with the present in vivo results 
showing that total testosterone levels in the plasma and liver and free testosterone levels in plasma 
were significantly increased in Cyp3a-/- mice (Figs. 12A and 12B). These findings suggest that 
CYP3A, perhaps hepatic CYP3A, is one of the important determinants that regulate systemic levels 
of testosterone in mice. In this connection, we showed that total testosterone levels were increased by 
1.8 fold and that free levels were increased by 9.0 fold in the plasma of Cyp3a-/- mice. This difference 
appears to come from the different free fractions of testosterone in plasma, which were calculated to 
be 37% and 7.2% in the plasma of Cyp3a-/- and WT mice, respectively. It seemed that binding of 
testosterone to serum proteins, such as SHBG, is saturated because of the increased levels of 
testosterone in plasma of Cyp3a-/- mice. In any case, the 9.0-fold increase in levels of free testosterone 
indicates that total clearance of free testosterone was decreased dramatically in Cyp3a-/- mice (11% 
of that in WT mice), suggesting that CYP3A is a major determinant regulating systemic levels of 
testosterone at least in mice.  
Since free testosterone diffuses into a target organ [58], a remarkable increase in free 
testosterone in plasma is expected to enhance androgen response in target organs including the prostate. 
In fact, the results of the present study showed testosterone levels and mRNA expression levels of all 
target genes of the AR examined in this study were significantly increased in the prostates of Cyp3a-/- 
mice (Figs. 12C and 13A). In addition, protein expression levels of SCAP were increased in the 
prostates of Cyp3a-/- mice (Fig. 13B). The results of ChIP assays also showed that specific binding of 
the AR to the ARE-containing region of the Sbp and Prkcd promoter [68, 69] was significantly more 
abundant in the prostates of Cyp3a-/- mice than in the prostates of WT mice (Fig. 13C). Furthermore, 
treatment with bicalutamide to Cyp3a-/- mice decreased the mRNA expression levels of AR target 
genes in the prostates (Fig. 15A). The fold decrease caused by bicalutamide were larger than the fold 
increase caused by Cyp3a deficiency, which implied bicalutamide diminished their physiological and 
induced expressions regulated by AR in the prostates of Cyp3a-/- mice. These findings suggest that 
androgen response via AR activation is stimulated in the prostate of Cyp3a-/- mice through the increases 
of prostatic testosterone levels. 
Activated AR has been reported to increase the expression of target genes of SREBP2 
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involved in cholesterol synthesis and transport through transactivation of SCAP, which enhances 
maturation of SREBP in LNCaP cells [11, 12]. In accordance with the findings using LNCaP cells, the 
present study showed that protein expression levels of SCAP and mRNA expression levels of SREBP2 
target genes involved in the synthesis and transport of cholesterol were increased in the prostates of 
Cyp3a-/- mice (Figs. 13B and 14B), and they were decreased by bicalutamide treatment to Cyp3a-/- 
mice (Fig. 15B). In addition, expression levels of mature SREBP2 were elevated in the prostates of 
Cyp3a-/- mice (Fig. 14A). Finally, total cholesterol levels were increased in the prostates of Cyp3a-/- 
mice (Fig. 14C). The findings suggest that Cyp3a deficiency increases testosterone in plasma and 
prostates, which enhances cholesterol synthesis via the SCAP-SREBP2 pathway in the prostate as 
reported previously in LNCaP cells [11, 12]. Although high cellular cholesterol levels suppress 
activation of SREBP2 [31], it seemed that SCAP-mediated activation of SREBP2 exceeded the 
cholesterol-mediated suppression of SREBP2 in the prostates of Cyp3a-/- mice. In addition, it has 
reported that transcription of Srd5a2 gene is enhanced by activated SREBP2 [71], suggesting that 
activated SREBP2 might increase mRNA expression levels of Srd5a2 in the prostates of Cyp3a-/- mice. 
In this context, we previously reported that SREBP2 was activated in the livers of Cyp3a-/- 
mice, possibly due to impaired synthesis of oxysterols (e.g., 25HC) which can suppress proteolytic 
activation of SREBP2 [31, 66]. Therefore, the results of this study may imply that the activation of 
SREBP2 in livers of Cyp3a-/- mice is also caused by an increased level of free testosterone. Further 
study is needed to clarify the impact of AR activation on SREBP2 activation in the livers of Cyp3a-/- 
mice. 
The present study showed that Cyp3a deficiency dramatically increased free testosterone in 
plasma, which stimulated androgen response and enhanced cholesterol synthesis in the prostate. 
Zhang et al. [18] reported that altered plasma level of testosterone affects androgen response 
including physiological development of prostate in castrated mice. However, we could not find any 
difference in the weight of prostate between Cyp3a-/- and WT mice (data not shown). In non-castrated 
mice, increased testosterone may not induce such physiological effects. On the other hand, this 
remains possible that increased testosterone and cholesterol levels affect the disease state of the 
prostate. For example, epidemiological evidence suggested that high levels of circulating testosterone 
is related to the risk of benign prostate hypertrophy and prostate cancer [72, 73]. In addition, high-fat 
diets increased the risk of prostate cancer by accumulation of cholesterol [74, 75], whereas 
cholesterol-lowering drugs (e.g., statins) reduced the risk of advanced prostate cancer [76, 77]. Thus, 
decreased activity of CYP3A may lead to deterioration of benign prostate hypertrophy and prostate 
cancer. 
In humans, CYP3A4/5, major isoforms of CYP3As in the liver, have variants that reduce the 
enzyme activities [78, 79]. In addition, Werk et al. [80] recently reported the first case of a complete 
failure of CYP3A enzyme activity due to homozygous loss-of-function mutation of CYP3A4 
combined with nonfunctional CYP3A5 [80]. Furthermore, a number of drugs used in clinical settings 
inhibit CYP3A activity [81]. In particular, drugs including antibacterials, anticancer agents, anti-HIV 
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agents, antihypertensives, sex steroids and their receptor modulators, and several herbal constituents 
cause potent and sustained inhibition of CYP3A [82], since they make CYP3A completely 
nonfunctional until it is replaced with newly synthesized one. Therefore, further studies are needed to 
clarify the effects of genetic mutations of CYP3A genes and treatments with these CYP3A-inhibiting 
drugs on systemic levels of free testosterone and their potential associations with prostate cancer and 
benign prostate hypertrophy in humans, as well as in disease model mice such as the transgenic 
adenocarcinoma of mouse prostate model. 
In conclusion, Cyp3a deficiency dramatically increased plasma testosterone levels, 
suggesting that CYP3A is a major determinant regulating systemic levels of testosterone at least in 
mice. The results also indicated that Cyp3a deficiency stimulated androgen response via AR activation 
in the prostate. Finally, Cyp3a deficiency increased cholesterogenic gene expression levels and total 
cholesterol contents in the prostate, which may be caused by activation of the SCAP-SREBP2 pathway. 
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Conclusions 
 
1. Deficiency of CYP3A enhances hepatic cholesterol synthesis through the activation of SREBP2, 
which appears to be triggered by the reduction of 25-HC and cholesterol in Cyp3a-/- mice.  
 
2. Enhancement of bile acid synthesis from cholesterol seems to be associated with the reduction of 
cholesterol levels in the livers of Cyp3a-/- mice. 
 
3. Deficiency of CYP3A dramatically increased plasma testosterone levels, suggesting that CYP3A 
is a major determinant regulating systemic levels of testosterone at least in mice.  
 
4. The increased testosterone levels in plasma might raise testosterone levels and activate AR in the 
prostates of Cyp3a-/- mice. 
 
5. Deficiency of CYP3A increased cholesterogenic gene expression levels and total cholesterol 
contents in the prostate, which may be caused by activation of AR and sequential stimulation of 
the SCAP-SREBP2 pathway.  
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